Immunocore (IMCR) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MeiraGTx (MGTX) has outperformed Immunocore (IMCR) over the past year, gaining 27.1% versus a loss of 14.4%. Over five years, IMCR leads with a -23.4% price change compared with -26.5% for MGTX. Immunocore is the larger company by market cap ($1.50 billion vs $1.01 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | MGTX |
|---|---|---|
| Share price | $29.09 | $10.50 |
| Market cap | $1.50B | $1.01B |
| 1-day change | -1.09% | -2.96% |
| YTD return | -16.19% | +32.08% |
| 1-year return | -14.42% | +27.12% |
| 5-year return | -23.45% | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-0.36 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $400.02M | — |
| Revenue growth (YoY) | +28.95% | — |
| Net income (latest FY) | $-35.51M | — |
| Gross margin | 98.73% | — |
| Operating margin | -11.34% | — |
| Net margin | -8.88% | — |
| 52-week high | $40.72 | $15.35 |
| 52-week low | $27.56 | $6.62 |
| Distance from 52-week high | -28.55% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.64% | +164.29% |
| Average volume | 443.48K | 792.38K |
| Shares outstanding | 51.50M | 96.04M |
| Employees | 524 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed IMCR by 41.5 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
IMCR vs MGTX FAQ
Which is bigger, Immunocore or MeiraGTx?
Immunocore (IMCR) is larger, with a market capitalization of $1.50B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, IMCR or MGTX?
MGTX returned +27.12% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.